Esperal Implant
Worldwide recognized as the most efficient treatment for alcohol addiction
French-based, Esperal Corporation, formerly known as Antabuse Implant Corporation, changed its name to Esperal Corporation on July 1, 2014, after selling its Antabuse business and the rights to brand name Antabuse on July 1, 2014.
Esperal specializes in the development and manufacturing of reliable, secure microchip-based implants for treatment of severe forms of alcoholism, leveraging its 30 year legacy of proficiency in pharmaceutical products for the treatment of addictions. Esperal delivers state-of-the-art products based on its product platforms and rehabilitation services. Complementing its pharmaceutical and nanotechnological solutions, Esperal offers proven and practical approach for alcohol addiction treatment.
Esperal accredited pharmaceutical laboratories are amongst the world’s best, delivering innovative pharmaceutical products to the manufacturers on six continents and in more than 47 countries. Customers choose Esperal Laboratories because we understand the importance of the issue and the effort that required from narcologists implementing this pioneering method. Esperal Laboratories have over 35 years of scientific, academic, and clinical experience, and provide analytical support to both physicians and manufacturers.
